Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma
Metrics: PDF 1537 views | HTML 1886 views | ?
Le Chang1,2, Guojing Wang1,2, Tingting Jia3, Lei Zhang1,4, Yulong Li1,2, Yanxi Han1, Kuo Zhang1,2, Guigao Lin1, Rui Zhang1, Jinming Li1,2, Lunan Wang1,2
1National Center for Clinical Laboratories, Beijing Hospital, Beijing, People's Republic of China
2Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
3Department of Clinical Laboratory, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China
4Peking University Fifth School of Clinical Medicine, Beijing, People's Republic of China
Jinming Li, e-mail: firstname.lastname@example.org
Lunan Wang, e-mail: email@example.com
Keywords: hepatocellular carcinoma, maternally expressed gene 3, MS2 virus-like particles, epidermal growth factor receptor, GE11
Received: January 21, 2016 Accepted: March 02, 2016 Published: March 16, 2016
Hepatocellular carcinoma (HCC) is one of the most frequently diagnosed cancers worldwide. However, the treatment of patients with HCC is particularly challenging. Long non-coding RNA maternally expressed gene 3 (MEG3) has been identified as a potential suppressor of several types of tumors, but the delivery of long RNA remains problematic, limiting its applications. In the present study, we designed a novel delivery system based on MS2 virus-like particles (VLPs) crosslinked with GE11 polypeptide. This vector was found to be fast, effective and safe for the targeted delivery of lncRNA MEG3 RNA to the epidermal growth factor receptor (EGFR)-positive HCC cell lines without the activation of EGFR downstream pathways, and significantly attenuated both in vitro and in vivo tumor cell growth. Our study also revealed that the targeted delivery was mainly dependent on clathrin-mediated endocytosis and MEG3 RNA suppresses tumor growth mainly via increasing the expression of p53 and its downstream gene GDF15, but decreasing the expression of MDM2. Thus, this vector is promising as a novel delivery system and may facilitate a new approach to lncRNA based cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.